Stockwinners Market Radar for June 11, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:56 EDT Quidel receives BARDA funding to develop point-of-care diagnostic assay - Quidel announced that it has received funding from the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to support the development of a point-of-care diagnostic assay that potentially tests for four respiratory viruses: SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus. The respiratory virus panel would be developed to run on Quidel's Sofia 2 flagship instrument.

18:42 EDT L3Harris Technologies CEO: Starting to see revenue synergies coming through - In an interview on CNBC's Mad Money, Bill Brown said the company is starting to see revenue synergies coming through from the merger. "We are a bigger player now with better technologies and synergies," Brown noted. "We are a technology-based company that sells into the defense space," he said. The company is looking at the whole portfolio and deciding which businesses drive value. It is generating a lot of cash flow, but is not focused on M&A right now, Brown noted.

18:31 EDT SPDR Gold Shares holdings rise to 1,135.05MT from 1,129.49MT - This is the 2nd consecutive increase and the highest level of holdings since April of 2013.

18:06 EDT Bristow Group completes merger with Era Group - Bristow Group (VTOL) and Era Group (ERA) announced that they have completed their combination. The newly combined company will use the Bristow Group name and will remain a publicly traded company on the New York Stock Exchange. The newly combined company's common stock will begin trading under the stock ticker "VTOL" beginning on June 12 and will have a new CUSIP number of 11040G103.

17:46 EDT Viela Bio announces FDA approval of Upliznatm - Viela Bio announced that the FDA has approved UPLIZNATM for the treatment of adult patients with neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive as a twice-a-year maintenance regimen following initial doses. Approximately 80%1 of all patients with NMOSD test positive for anti-AQP4 antibodies. NMOSD is a rare, severe, neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord and brain stem.

17:23 EDT Lockheed Martin, others awarded maximum $10.27B ATSP4 contract modifications - Lockheed Martin (LMT); BAE Systems (BAESY); General Dynamics (GD); Northrop Grumman (NOC); Raytheon (RTX); Boeing (BA) and Honeywell (HON), are being awarded a maximum $10.27B modification on existing indefinite-delivery/indefinite-quantity, Advanced Technology Support Program IV, or ATSP4, contracts. The modification raises the ceiling on the current ATSP4 contracts from $7.2B to $17.47B. ATSP4 are multiple-award, indefinite delivery/indefinite quantity contracts for engineering services designed to resolve problems with obsolete, unreliable, unmaintainable, underperforming, or incapable electronics hardware and software through development of advanced technology insertions and applications to meet the requirements of the Department of Defense for a quick reaction capability. With all options exercised, the ordering period goes until March 31, 2026. The contracts were competitively procured via a February 2015 solicitation resulting in nine proposals and eight awards. No funds are being obligated on award. Funding will occur through individual task orders. The Defense Microelectronics Activity is the contracting activity.

17:18 EDT Selecta Biosciences, Sobi announce strategic licensing agreement for SEL-212 - Swedish Orphan Biovitrum AB, or Sobi, and Selecta Biosciences announced that the companies have entered into a strategic licensing agreement for the product candidate SEL-212. SEL-212 is a combination of Selecta's tolerogenic ImmTOR immune tolerance platform and a therapeutic uricase enzyme that is designed to durably control serum uric acid, reduce immunogenicity, and allow for repeated monthly dosing for the treatment of chronic refractory gout. Under the terms of the license agreement, Sobi will assume responsibility for development, regulatory, and commercial activities for SEL-212 in all markets outside of China. Sobi will make initial payments to Selecta of $100M, which include $75M up-front license fee and $25M in a private placement of shares of Selecta common stock. Selecta is eligible to receive potential milestone payments of up to $630M from Sobi, which are dependent upon specific regulatory and development targets having been met, as well as sales thresholds. Additionally, Selecta is eligible to receive tiered double-digit royalties on net sales. Sobi and Selecta have entered into a share purchase agreement, pursuant to which Sobi will invest $25M in a private placement of 5,416,390 shares of Selecta common stock at a purchase price of $4.62 per share. The transaction is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act and other customary closing conditions. Sobi intends to finance the considerations above by available funds.

17:16 EDT Hamilton Beach provides update on Q1 - The company said, "The first quarter began with strong momentum across all markets. Revenue was trending ahead of prior year until government measures to control the spread of COVID-19 were implemented and the quarter ended an estimated 4% to 5% behind the prior year first quarter. In the U.S. and Canada, consumer demand was strong for many small kitchen appliance categories as stay-at-home orders led to an increased focus on basic needs such as food and beverage preparation. Revenue from these markets provided stability for category demand and held steady to prior year. Sales of "Only-the-Best" or premium products increased. Ecommerce sales increased significantly and accounted for more than 25% of total revenue. On the other hand, revenue from the International Consumer and Global Commercial markets decreased due to the adverse impact of the COVID-19 pandemic." Inventory levels decreased significantly as a result of ongoing inventory control, strong supply chain management during the challenging COVID-19 environment faced by the company's third-party suppliers and pandemic-related orders from certain retailers. Additionally, as expected, due to the late order pattern in the 2019 holiday selling season, trade receivables in Q1 decreased significantly compared to Q4 of 2019. For the three months ended March 31, net cash used for operating activities from continuing operations was approximately $10M, an improvement that resulted from changes in net working capital. Capital expenditures were $600,000. Debt was $69.5M at March 31 and reflected reduced inventory and improved cash flow. There were no share repurchases during the first quarter. The company will also issue an earnings release for Q1 and hold an investor conference call, the dates of which will be announced in a future press release.

17:13 EDT Hamilton Beach says financial statements for 2018, 2019 should not be relied on - Hamilton Beach announced that in connection with its previously disclosed investigation into certain accounting irregularities at its subsidiary in Mexico, the audit review committee of the board, after discussion with the company's management and its independent registered public accounting firm, concluded that the company's previously issued consolidated financial statements for the years ended December 31, 2019 and 2018, each of the quarters during the years ended December 31, 2019 and 2018, and other financial data relating to these periods should no longer be relied upon. The company intends to file restated consolidated financial statements for all periods referenced above as soon as practicable. As disclosed on May 11, the company discovered the accounting irregularities during the quarter ended March 31. The company's audit review committee commenced an internal investigation with the assistance of outside counsel and other third party experts. As a result of the investigation, the company, along with the committee and its third party experts, concluded that certain employees of the company's Mexican subsidiary engaged in unauthorized transactions with the company's Mexican subsidiary that resulted in the recording of assets that are not realizable. As a result, the company will record a non-cash write-off for certain amounts erroneously included in the company's historical financial statements in trade receivables, prepaid expenses and other current assets and will restate its financial statements for the years ended December 31, 2019 and 2018 and each of the quarters during the years ended December 31, 2019 and 2018. The company estimates the impact of these adjustments to be a reduction to net income from continuing operations in the range of approximately $6M-$9M for the year ended December 31, 2019 and $4M-$6M for the year ended December 31, 2018. These preliminary estimates are based on currently available information and are subject to change during the course of the ongoing investigation. The investigation is continuing and there is no assurance that additional items will not be identified.

17:04 EDT Flexsteel Industries COO Derek Schmidt buys over $418K in company shares - Flexsteel Industries COO Derek Schmidt disclosed in a filing that he had purchased 35,506 shares of company stock at $11.78 per share between June 9 and June 11. The total transaction value of the purchase was $418,346.

17:03 EDT Black Stone Minerals enters new DUCs incentive agreement with XTO Energy - Black Stone Minerals announced it has entered into a new incentive agreement with XTO Energy with respect to certain drilled but uncompleted wells, or DUCs, in the company's Shelby Trough acreage in San Augustine County, Texas. The agreement allows for royalty relief on 13 existing DUCs if XTO completes and turns the wells to sales by March 31, 2021, and complements the recent development agreement with Aethon Energy covering the company's Shelby Trough acreage in Angelina County towards Black Stone's goal of reviving volume growth from the area. In addition to the agreement covering the DUCs, Black Stone is actively evaluating alternatives to encourage further development activity in the Shelby Trough in San Augustine through a combination of working with XTO and utilizing the company's available acreage position and contractual rights to bring in a second operating partner

17:01 EDT Independence Holding Co. resumes stock repurchase program - Independence Holding Co. has resumed purchasing its shares of common stock in open market transactions under its stock repurchase program now that the ten business day period after the expiration of its recent tender offer to purchase up to 1M shares has expired. Under the current repurchase program, IHC may repurchase up to 1,659,208 shares of its common stock, from time to time, in the open market subject to applicable rules. In addition, IHC may repurchase shares under the repurchase program through privately negotiated transactions.

16:41 EDT Adobe expects 'typical seasonal strength in Q4', op. expense in line w/ growth - The company states: "We expect typical seasonal strength in Q4 across our Digital Media and Digital Experience business. We expect our operating expenses to increase in line with growth rates in previous years as we continue to invest for growth." Comments taken from investor presentation slides.

16:30 EDT W.P. Carey raises quarterly dividend to $1.042 from $1.04 per share - The dividend is payable on July 15, 2020 to stockholders of record as of June 30, 2020.

16:26 EDT Lender impacted by COVID-19, asks Tilray to withdraw $9.9M loan request - "On June 5, through its wholly owned subsidiary High Park Holdings entered into a First Amendment to its existing $60 million senior credit agreement dated as of February 28, among Bridging Finance as agent for and on behalf of any of the funds managed or co-managed by Bridging Finance, collectively, certain guarantors and the Borrower. As a result of COVID-19 related financial markets conditions that have affected the Lender, and not because of any material changes to the business of Tilray or its subsidiaries, the Lender requested that Tilray withdraw its outstanding request for the additional funding of $9.9M under the Senior Credit Facility. In exchange for Tilray's accommodation of the Lender's request to withdraw its funding request, the Lender agreed to enter into the First Amendment of the Senior Credit Facility. Among other things, the First Amendment provides that the Senior Credit Facility will only require interest payments for the remainder of its term. All outstanding principal payments will be due at maturity, February 28, 2022. Additionally, and at such time as the Lender's business may allow, the Lender may make the additional proceeds of $9.9M available during the term of the Credit Agreement, at its sole discretion. Tilray has been, and is currently, in full compliance with all terms of the Senior Credit Facility and will not incur any fees or penalties in connection with the First Amendment," said the company in an 8k filing.

16:20 EDT Lululemon falls 6% to $289.00 after Q1 results miss estimates

16:18 EDT PVH Corp. sees Q2 sales for reopened stores quarter-to-date down 25% globally - The company states: "By mid-June, over 85% of the company's stores globally are expected to be reopened. Sales for reopened stores for the second quarter-to-date are running down approximately 25% globally compared to the prior year period."

16:17 EDT Wins Finance 'not aware' of any developments to account for trading activity - Wins Finance announced that that while it ordinarily does not comment on market activity or market speculation, in view of the recent high trading volume and significant price increase of the company's ordinary shares, Wins Finance wanted to confirm to the market that it is not aware of any material corporate developments that could account for this unusual trading activity.

16:12 EDT Despegar.com acquires Best Day Travel for $56.5M - As a result of negotiations undertaken in response to the substantial effects of the COVID-19 crisis on the global travel and OTA industries, Despegar and Best Day have agreed on the following terms: Base consideration of approximately $56.5M . An additional variable purchase price component, ranging from zero to $20M, payable 48 months following the closing date. The variable component will be based on the performance of Despegar's share price during a six month period prior to the fourth anniversary of the closing date. These revised terms reflect a reduction from consideration of $136M announced on January 27, 2020, a portion of which was payable on a deferred basis and subject to adjustment based on performance.

16:10 EDT Lululemon says all retail locations in Mainland China have reopened - Calvin McDonald, CEO of Lululemon, said: "I'm proud of how lululemon has navigated these unexpected and unprecedented times. We are learning more every day about our guests -- how they enjoy interacting with us online and what makes them comfortable as stores reopen. Our strong digital business demonstrates the strength of our guest connection and the long-term opportunity to create further Omni experiences going forward." The company added that it has taken actions to close retail locations and to reduce operating hours, and it continues to monitor the situation and work closely with local authorities to prioritize the safety of its people and guests. "In February 2020, the company temporarily closed all of it retail locations in Mainland China. All of these locations have since reopened. In March 2020, it temporarily closed all of its retail locations in North America, Europe, and certain countries in Asia Pacific. Subsequent to May 3, 2020, the company began reopening its retail locations in these markets in line with the guidance from local authorities. As of June 10, 2020, 295 of its company-operated stores were open. The company's retail locations and distribution centers are operating with precautionary measures in place such as reduced operating hours, physical distancing, enhanced cleaning and sanitation, and maximum occupancy levels," Lululemon said.

16:10 EDT Adobe reports Q3 Digital Media segment revenue up 18% at $2.23B - The company states: "Digital Media segment revenue was $2.23B, which represents 18% year-over-year growth. Creative revenue grew to $1.87B and Document Cloud revenue was $360M. Digital Media Annualized Recurring Revenue ("ARR") grew to $9.17B exiting the quarter, a quarter-over-quarter increase of $443M. Creative ARR grew to $7.93B, and Document Cloud ARR grew to $1.24B."

16:08 EDT Adobe withdraws FY20 guidance - The company states: "In light of the macroeconomic environment and the strategic shifts for Advertising Cloud, Adobe is withdrawing the annual fiscal 2020 targets provided in December 2019."

16:07 EDT Tilt Holdings CFO David Caloia departs company - TILT Holdings announced that TILT's Chief Financial Officer, David Caloia, will depart the Company effective June 12. Brad Hoch, Controller at the company's Jupiter Research, business unit, will assume responsibilities as the interim TILT CFO and Corporate Controller while the Company completes its search for a permanent CFO.

16:03 EDT HTG Molecular signs three new European distributor agreements - HTG Molecular announced the signing of three new European distributor agreements to promote HTG products and services in Nordic and Eastern European Countries with BioNordika in Denmark, Explorea in Czech Republic and ELTA 90 in Bulgaria. "Expanding and strengthening our distribution network into these European markets is another important growth step for HTG," said Jean Claude Gerard, senior VP of European operations. "Working closely with these distributors will improve our ability to reach new customers with our HTG EdgeSeq technology, which we believe will further accelerate our molecular profiling and diagnostic growth opportunities in the region this year."

15:17 EDT Crypto firm BitPay launches prepaid Mastercard in the U.S, with instant loads - Crypto firm BitPay announces prepaid Mastercard. The company said in an earlier blog posting: "BitPay is excited to announce the release of the first ever US prepaid Mastercard that can be loaded with dollars that are converted from cryptocurrency. With instant card reloads, no conversion fees, a $10,000 daily load and spending limit, and the ability to spend at millions of locations worldwide, the new BitPay Card will enable you to live your life on crypto. Reference Link

15:06 EDT Triumph Group awarded four-year contract for HUA valves on F-35 - Triumph Group (TGI) announced that its Triumph Systems & Support business was awarded a four-year contract for hydraulic utility actuation, or HUA, valves on the F-35. The long-term agreement extends an existing two-year order with Lockheed Martin (LMT) and makes Triumph Group the sole provider for the HUA valve statement of work, the company said.

14:57 EDT Tonix acquires migraine, pain treatment programs of Trigemina - Tonix Pharmaceuticals Holding Corp. announced an agreement whereby Tonix will acquire the migraine and pain treatment technologies of Trigemina, and will assume the license for some of the technologies from Stanford University. The lead asset, TNX-1900 is a proprietary, patented enhanced formulation of nasal oxytocin, with demonstrated activity in several non-clinical studies in pain including migraine prophylaxis and neuropsychiatric models and with safety data from non-U.S. studies.

14:32 EDT National Fuel raises dividend to 44.5c from 43.5c per share - National Fuel Gas Company's board of directors approved a 2.3% increase in the dividend on the company's common stock, raising the quarterly rate from 43.5c per share as approved in June 2019 to 44.5c per share for an annual rate of $1.78 per share. This dividend is payable July 15 to shareholders of record at the close of business on June 30.

13:51 EDT Snapchat in partnership with Zynga, Mojiworks - Snapchat (SNAP) announced that "Bitmoji Paint, from Snap Games Studio, brings together millions of players to simultaneously contribute to one global collage. An all-new infrastructure service will power this game, and soon, developers will be able to use these tools to build games for the Snap platform. We're also introducing new games from partners including Mojiworks, Game Closure, Zynga (ZNGA) and more!" Reference Link

13:47 EDT Snap announces new developer products and partnerships - Snap announced new developer products and partnerships across the Snap Kit, Snap Games and Bitmoji ecosystems. Snap also introduced Snap Minis, which it calls "a new way for developers to bring experiences inside Snapchat while leveraging the social power of the platform." These new developer products and partner integrations will launch throughout 2020. The company said: "More than 800 apps have integrated with Snap Kit, and nearly 150 million Snapchatters are engaging with these integrations every month. Since its launch in April 2019, more than 100 million Snapchatters have played Snap Games. Snap Minis, a new developer product, are built on the same core principles and technologies as Snap Games."

13:39 EDT American Axle sees having 'at least' $1.2B of liquidity at June 30 - In a regulatory filing earlier, American Axle said: "In March of 2020, COVID-19 was designated by the World Health Organization as a pandemic illness and began to significantly disrupt global automotive production. In an effort to mitigate the spread of COVID-19, many governmental and public health agencies in locations in which we operate implemented shelter-in-place orders or similar measures. Substantially all of our customers ceased or significantly reduced production, and the decline in production volumes has continued into the second quarter of 2020. As a result, substantially all of our manufacturing facilities have either temporarily suspended production or experienced significant reductions in volumes during this period. By the end of the first quarter of 2020, our manufacturing locations in Asia were beginning to stabilize and return to more normalized levels of production... At March 31, 2020, we had over $1.4 billion of liquidity consisting of approximately $683 million of cash and cash equivalents, approximately $691 million of available borrowings under our Revolving Credit Facility and approximately $86 million of available borrowings under foreign credit facilities. Further, we have no significant debt maturities before October 2022. Based on our liquidity profile and no significant debt maturities in 2020, as well as the measures that we are taking to conserve cash, we believe that we will have sufficient funds available to continue operating with no significant changes to our capital structure until such time as production returns to more normalized levels...As an update, during the month of May 2020, AAM restarted its operations in North America and Europe and is currently in the process of ramping up production, along with our customers and supply base. In addition, AAM expects to have at least $1.2 billion of liquidity at June 30, 2020."

13:23 EDT UK's competition watchdog probes Viagogos purchase of eBay's Stubhub unit - The U.K.'s Competition and Markets Authority or CMA said in a posting to its website: "The Competition and Markets Authority, CMA, is concerned that the loss of competition brought about by the merger could result in customers who buy and resell tickets losing out as a result of higher prices and fewer options. viagogo purchased StubHub in February 2020. Both companies have a significant presence in the UK's secondary ticketing market. Together, they have a combined market share of more than 80% and are the number 1 and number 2 players respectively in the UK. After completing its initial Phase 1 investigation, the CMA found that viagogo and StubHub are close competitors in an already very concentrated market with limited alternatives. It is particularly concerned that the merger would raise the prices for customers, including fans, who resell and buy secondary tickets to live events. As part of its investigation, the CMA undertook extensive market testing and looked at evidence from a number of third-party stakeholders including consumer groups, customers and competitors. It also examined the companies' internal documents." Reference Link

12:57 EDT Gogo drops 13% to $2.61 after Delta seeks second Wi-Fi supplier

12:52 EDT Night Market Research says value of Zynex business 'near zero' - Zynex "revenue growth masks deteriorating profitability," Night Market Research said in a recently publish report in Seeking Alpha. "Zynex (NASDAQ: ZYXI) shares are up 150% year to date vs the Health Care Select SPDR ETF (NYSE: XLV) at -2%. We believe ZYXI's outperformance is a function of retail investor complacency combined with sell-side analyst carelessness and leaves the stock extremely vulnerable to a major repricing lower," it added. "We now believe the value of the business is near zero and the most probable outcome for shareholders is near total losses." In afternoon trading, shares of Zynex have gained 10% to $23.33. Reference Link

12:32 EDT Facebook responds to Biden, says will protect political speech - Facebook issued a statement after the Biden campaign released a petition and open letter to the company. Facebook said in response: "We live in a democracy, where the elected officials decide the rules around campaigns. Two weeks ago the President of the United States issued an executive order directing Federal agencies to prevent social media sites from engaging in activities like fact-checking political statements. This week, the Democratic candidate for President started a petition calling on us to do the exact opposite. Just as they have done with broadcast networks - where the US government prohibits rejecting politicians' campaign ads - the people's elected representatives should set the rules, and we will follow them. There is an election coming in November and we will protect political speech, even when we strongly disagree with it."

12:30 EDT Korn/Ferry names Michael Hyter as chief diversity offiver - Korn Ferry announced that Michael Hyter has been appointed as the firm's Chief Diversity Officer. He will report directly to Korn Ferry CEO Gary Burnison and join the senior executive team. Hyter joined Korn Ferry in 2012 after the acquisition of Global Novations. "I'm thrilled Mike is assuming the role of Chief Diversity Officer. He is the right person, at the right time to further our embrace of diverse perspectives and backgrounds and drive meaningful change within Korn Ferry and with clients," said Burnison.

12:21 EDT Biden demands Facebook change its polices to stop spread of disinformation - Senator and presidential candidate Joe Biden said via Twitter: "So far, Facebook has failed to enact any real reforms to stop the spread of disinformation on its platform. Time is running out. Today, we're releasing an open letter demanding the company change its policies." In the letter, Biden says: "Our asks are pretty simple: They need to promote authoritative and trustworthy sources of election information, rather than the rants of bad actors and conspiracy theorists. They need to promptly remove false, viral information; They need to prevent political candidates and PACs from using paid advertising to spread lies and misinformation - especially within two weeks of election day; They need clear rules - applied universally, with no exceptions for the President - that prohibit threats and lies about how to participate in the election. We're now less than 150 days to the election. The time for setting, testing, and implementing meaningful policy to protect our elections is running out. We need to move fast and fix Facebook now. " Reference Link

12:07 EDT Interparfums, Moncler sign license agreement for fragrances - Moncler and Interparfums signed an exclusive and worldwide license agreement for fragrances which will last till December 31st, 2026, with a potential 5-year extension. Under such agreement, Interparfums will create and produce perfumes and fragrance-related products and will distribute them in Moncler monobrand stores as well as selected department stores, specialty stores and duty-free shops. The launch of the first fragrance line is expected within the first quarter of 2022.

12:00 EDT Small Cap Bear 3x rises 16.2% - Small Cap Bear 3x is up 16.2%, or $3.47 to $24.93.

11:54 EDT Potbelly denies report of hiring Alvarez and Marsal as restructuring adviser - After Richard Collings reported earlier this week in Adweek that Potbelly had hired Alvarez and Marsal as its restructuring adviser and was said to be weighing its financial options, including bankruptcy, the company said in a tweet that linked back to the Adweek report: "we have not engaged this firm and have no plans to do so." Reference Link

11:34 EDT Usana issues patent for InCelligence Complex formula - Usana is proud to announce it has been issued a groundbreaking US patent for its In Celligence Complex formula. The patent, US Pat. No. 10,632,101, is unique to the health and wellness industry. It recognizes the InCelligence Complex formula contains antioxidant compounds that support endogenous systems associated with optimal lifespans. The patent was submitted by USANA R&D scientists, Drs. Mark Brown, Jeremy Tian, and John Cuomo.

11:27 EDT Myriad Genetics 'encouraged' by issuance of pharmacogenomic LCD by Palmetto GBA - Myriad Genetics acknowledges the release of a final local coverage determination for pharmacogenomic testing by Palmetto GBA, one of the administrative contractors for the Centers for Medicare & Medicaid Services. The new LCD does not restrict PGx testing by provider type as long as the provider has the licensure, qualifications, and necessary experience / training to both diagnose the condition being treated and also to prescribe medications. The LCD provides coverage across a range of psychiatric conditions.The new LCD is a limited coverage policy for PGx testing that establishes coverage for single-gene and multi-gene tests. While Palmetto states that there are insufficient data to support coverage of combinatorial tests, the LCD notes "that combinatorial tests are a subtype of multi-gene PGx tests, and there may be components within those tests that are necessary and reasonable and thus may be covered." Though this Palmetto GBA LCD is final, details of its application to GeneSight Psychotropic testing await action by CGS Administrators, LLC, the Medicare Administrative Contractor for the GeneSight test. "We are encouraged by the issuance of a pharmacogenomic LCD with broad coverage of tests ordered by any licensed physician for the treatment of a range of psychiatric conditions," said Mark S. Verratti, president of Myriad Neuroscience and Myriad Autoimmune. "We believe GeneSight is covered under the new LCD as a multi-gene panel and await a Local Coverage Article for GeneSight and specific action by CGS. Multiple clinical studies have demonstrated the clinical value of the GeneSight Psychotropic combinatorial test."

11:03 EDT Under Armour CEO: Sportsmask 'sold out in less than an hour' - Under Armour CEO Patrik Frisk, responding to a question via Twitter from CNBC's Courtney Regan, said the company's Sportsmask, a performance mask engineered to equip athletes returning to training, "sold out in less than an hour. More will become available in July." Reference Link

10:55 EDT BOK Financial appoints Sean Hampton as CMO - BOK Financial has named Sean Hampton SCP, chief marketing officer. Hampton will develop new marketing initiatives to drive growth, spur innovation and steward the company's brand across all lines of business and the company's eight-state footprint. He will also play an important role in shaping the company's analytics and martech strategy to increase scalable growth and bottom-line revenue growth. Hampton joins BOK Financial after 20 years with Janus Henderson where he served as global head of marketing technology strategy and execution.

10:28 EDT Barclays names Georgi Balinov head of global technology payments banking - Barclays (BCS) announces the appointment of Georgi Balinov as Head of Global Technology Payments Banking. Balinov will be based in New York, and will report to Marco Valla, Global Head of Technology, Media and Telecommunications Banking at Barclays. Balinov joins Barclays with over fifteen years of experience in banking, most recently as Head of FinTech Americas within the Financial Institutions Group at Bank of America Merrill Lynch (BAC). In this role he was responsible for financial technology investment banking coverage across the payments, financial software and data sectors.

10:04 EDT Entertainment Studios Networks and Comcast announce content carriage arrangement - Entertainment Studios Networks and Comcast announced they have entered into a content carriage arrangement that extends and amends terms for The Weather Channel and 14 broadcast television stations. The deal also includes distribution of Comedy.TV, Recipe.TV and JusticeCentral.TV on X1 and video on demand and TV everywhere rights for those networks. Comcast will also launch the free ad-supported digital app, Local NOW, on the Xfinity X1 and Flex platforms, and Xfinity customers who receive The Weather Channel will have access in the coming months to its weloveweather.tv website and app on an authenticated basis. The companies also announced that pending litigation between the two organizations has been withdrawn. Additionally, financial terms of the agreement were not disclosed.

10:00 EDT Helix Energy falls -18.3% - Helix Energy is down -18.3%, or -87c to $3.88.

10:00 EDT Oil States falls -19.2% - Oil States is down -19.2%, or -$1.18 to $4.98.

10:00 EDT Small Cap Bear 3x rises 13.2% - Small Cap Bear 3x is up 13.2%, or $2.83 to $24.29.

09:59 EDT GrubHub CEO says U.S. competitors' strategies won't work over long-term - GrubHub CEO Matt Maloney says the deal with Just Eat will mean GrubHub will have the financial strength to be "as competitive as we need to be" to continue to take back share in U.S.

09:50 EDT GrubHub CEO says board had 'very easy decision,' took 'much higher offer' - GrubHub (GRUB) CEO Matt Maloney said the company's board had "a very easy decision to make" in taking a "much higher offer" with "much more deal certainty." Just Eat "believes in our story, believes in our execution," said Maloney, who added that "we are winning back share." Maloney is being interviewed on CNBC after his company entered into a definitive agreement to be acquired in an all-stock deal by Just Eat Takeaway.com (TKAYY).

09:47 EDT AG Mortgage falls -25.0% - AG Mortgage is down -25.0%, or -$1.56 to $4.68.

09:47 EDT Direxion Financial Bear 3x rises 12.8% - Direxion Financial Bear 3x is up 12.8%, or $2.01 to $17.73.

09:47 EDT ProShares Trust Ultra VIX Short Term Futures ETF rises 14.3% - ProShares Trust Ultra VIX Short Term Futures ETF is up 14.3%, or $4.35 to $34.69.

09:38 EDT AG Mortgage trading resumes

09:35 EDT Macerich trading resumes

09:33 EDT AG Mortgage trading halted, volatility trading pause

09:30 EDT Macerich trading halted, volatility trading pause

09:30 EDT Diana Shipping announces time charter contract for m/v Los Angeles - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Engelhart CTP Freight SA, for one of its Newcastlemax dry bulk vessels, the m/v Los Angeles. The gross charter rate is $14,250 per day, minus a 5% commission paid to third parties, for a period until minimum October 1, 2021 up to maximum December 31, 2021. The charter commenced on June 6, 2020. The m/v Los Angeles was chartered, as previously announced, to SwissMarine Services S.A., Geneva, at a gross charter rate of $13,250 per day, minus a 5% commission paid to third parties. The "Los Angeles" is a 206,104 dwt Newcastlemax dry bulk vessel built in 2012. This employment is anticipated to generate approximately $6.77 million of gross revenue for the minimum scheduled period of the time charter.

09:14 EDT Novo Nordisk to acquire Corvidia Therapeutics to expand cardiovascular presence - Novo Nordisk announced that it has entered into a definitive agreement to acquire Corvidia Therapeutics, a privately held, clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Corvidia Therapeutics for an upfront payment of $725M in cash. Total payments to Corvidia Therapeutics shareholders could ultimately amount to $2.1B in cash upon the achievement of certain regulatory and sales milestones by Novo Nordisk, the company said. "The transaction will not impact Novo Nordisk's previously communicated operating profit outlook for 2020. Novo Nordisk will fund the upfront payment from financial reserves and the ongoing share buyback programme will not be impacted. The acquisition of Corvidia Therapeutics and its lead candidate, ziltivekimab, is aligned with Novo Nordisk's strategy to expand its presence across a range of cardiometabolic diseases that are closely linked to Novo Nordisk's core business within diabetes and obesity. Ziltivekimab is being evaluated in a phase 2b dose-finding clinical trial in patients who have an increased risk of atherosclerotic cardiovascular disease, or ASCVD, with chronic kidney disease, or CKD, and inflammation," Novo Nordisk added.

09:12 EDT Cinedigm partners with SPI to distribute Gametoon, FashionBox channels - Cinedigm announced a partnership with global media company SPI International to launch two new ad-supported streaming channels, Gametoon and FashionBox HD. Cinedigm will launch and distribute the ad-supported networks in North America and will work closely with SPI International on the marketing, audience development and monetization of the channels. SPI International operates 42 television channels with more than 65 million subscribers on six continents and is one of the largest aggregators of native Ultra HD content in the world. Both channels will be offered as free ad-supported linear channels, as AVOD, and as a la carte apps across Cinedigm's distribution footprint of more than 300 million devices across connected televisions, set-top-boxes, mobile & handheld devices, and virtual MVPDs.

09:08 EDT Sinovac Biotech, Instituto Butantan collaborate to advance CoronaVac trials - Sinovac Biotech and Instituto Butantan announced the signing of a clinical development collaboration agreement to advance the clinical trials of CoronaVac, Sinovac's inactivated vaccine candidate against COVID-19 to Phase III. Sinovac has made progress in the development of CoronaVac. Preclinical results regarding CoronaVac were recently published in the peer-reviewed academic journal Science in an article stating that the vaccine candidate is safe and provides protection to monkeys through an animal challenge study. Sinovac has received approval from China's National Medical Products Administration, or NMPA, to conduct Phase I/II human clinical trials in China to determine the vaccine candidate's safety, tolerance, dosage and immunization schedule. In addition, Sinovac is constructing a commercial vaccine production plant in China that is expected to manufacture up to 100M doses of CoronaVac annually. Through this collaboration, Instituto Butantan will sponsor Phase III clinical trials in Brazil. This is the first in a series of agreements expected to be completed between the parties to establish collaboration that includes technology licensing, market authorization and commercialization of CoronaVac. In this way, Instituto Butantan can ensure that the Brazilian population has access to this vaccine.

09:07 EDT Medtronic receives CE Mark for MiniMed 780G system - Medtronic announced CE Marking of its MiniMed 780G system, a next generation closed loop insulin pump system for the treatment of type 1 diabetes in people age 7 to 80 years. Leveraging the company's most advanced SmartGuard algorithm, the system automates the delivery of both basal insulin and correction boluses every five minutes to help people with diabetes avoid highs and lows with greater ease. The MiniMed 780G system enables the personalization of glucose goals with an adjustable target setting as low as 100 mg/dL - lower than any other advanced hybrid closed loop system - and is designed to help stabilize blood sugar levels and further improve glucose control. The system is expected to begin shipping this Fall in select countries in Europe. In the United States, the MiniMed 780G system is investigational use only and not approved for sale. The data from three trials using the next generation advanced hybrid closed loop system from Medtronic will be presented in a symposium at the virtual 80th Scientific Sessions of the American Diabetes Association.

09:05 EDT Lear expands Pine Grove production capacity to 500,000 face masks per week - Lear has added new equipment to its operations in Pine Grove, Pa., to make up to 500,000 protective face masks per week. The Pine Grove facility is among 10 Lear plants on three continents that are now producing masks for front line workers, local communities and company employees to help prevent the spread of COVID-19. In addition to Pine Grove's output, company employees are currently producing 600,000 masks at other global locations each week. Lear's facility in Mocksville, N.C., is also making face shields, including about 60,000 units in April.

09:03 EDT Digerati Technologies strengthens balance sheet by $1M - Digerati Technologies announced that the Company has retired $1.021M of debt. Out of operational cash flow, the Company fully paid and retired $281,000 in related party debt that matured April 30, 2020 and settled and converted $740,000 in shareholder debt to equity. The payment of the debt will improve cash flow from operations and eliminates the note payable for $281,000 and related interest. The conversion of debt to equity eliminated multiple notes payable from the Company's balance sheet and the related interest accruals and payments

08:50 EDT Emergent to be manufacturing partner for AstraZeneca's COVID-19 vaccine - Emergent BioSolutions (EBS) announced it will deploy its molecule-to-market contract development and manufacturing services to support the manufacturing of AstraZeneca's (AZN) vaccine candidate for COVID-19, AZD1222, a viral vector-based, weakened version of adenovirus containing the genetic material of SARS-CoV-2 spike protein, developed by Oxford University's Jenner institute working with the Oxford Vaccine Group. AstraZeneca's AZD1222 is one of several candidates supported by Operation Warp Speed, the U.S. government's program to accelerate the development, manufacturing, and distribution of COVID-19 medical countermeasures that aims to have substantial quantities of a safe and effective vaccine available for Americans by January 2021. As part of OWS, Emergent will provide development and manufacturing services and capacity to innovators of leading COVID-19 vaccine candidates selected by the U.S. government, such as AstraZeneca. Under the agreement, valued at approximately $87M, Emergent will provide development services, technology transfer, analytical testing, drug substance process and performance qualification and will reserve certain large-scale manufacturing capacity through 2020. Development services will be provided out of Emergent's Gaithersburg product development facility. Large-scale manufacturing of drug substance will be done at the Baltimore Bayview facility, an HHS-designated Center for Innovation in Advanced Development and Manufacturing designed for rapid manufacturing of large quantities of vaccines and treatments during public health emergencies.

08:43 EDT Ideanomics and Beijing Silk Road develop EV bus plan for China orders - Ideanomics' subsidiary, Mobile Energy Global, and Beijing Silk Road Rainbow Group have developed a new energy bus plan to help facilitate the sale of more than 2,000 EV buses in China through selecting manufacturers with the capability to fulfill multiple large-scale orders. The EV bus manufacturers include CRRC, Zhong Tong, Shanghai Shenli, and Yunnan Wulong. The Chinese government mandated that bus operators must convert or replace their bus equipment with clean energy vehicles by the end of 2022.

08:39 EDT Mack-Cali Realty reconstitutes slate of Board nominees for postponed Meeting - Mack-Cali Realty has entered into an agreement with Bow Street in connection with the postponement of the company's 2020 Annual Meeting of Stockholders. The Mack-Cali Board of Directors will promptly be reconstituted to be comprised of the following nine directors, eight of whom were nominated by Bow Street and one of whom was nominated by the company, in connection with the 2020 Annual Meeting: Alan Batkin, Michael Berman, Frederic Cumenal, MaryAnne Gilmartin, Tammy Jones, Akiva Katz, Nori Gerardo Lietz, Mahbod Nia, and Howard Stern. Alan Bernikow, Michael DeMarco, William Mack, Lisa Myers, Laura Pomerantz, Irvin D. Reid and Rebecca Robertson will resign as directors of the company. Mack-Cali has postponed the 2020 Annual Meeting, originally scheduled to be held on June 10, until July 1. The reconstituted Board will oversee the company pending the 2020 Annual Meeting. The company will formally nominate the revised slate of nine candidates to allow time for the company to update and distribute to shareholders proxy materials that reflect the revised slate. The Meeting will be held as a virtual-only meeting.

08:37 EDT Genasys announces $2.4M in international border, homeland security orders - Genasys announced $2.4M in orders for LRAD 500X and LRAD 1000X acoustic hailing devices and accessories from three countries. A country in Southeast Asia will use the LRAD 500X systems for homeland and border security applications, and the LRAD 1000X systems for vessel-mounted offshore security operations. Both follow-on orders are part of multi-year programs for communication solutions to enhance security procedures. Vehicle-mounted LRAD 500X systems are being deployed by two African nations for homeland security and public safety applications. Subsequent orders are expected from one of the countries.

08:35 EDT BioVie to commence Phase 2 study of BIV201 this year - BioVie announced that following the company's successful Phase 2a study, it has received guidance from the US Food and Drug Administration regarding the next clinical trial design for BIV201 in patients with refractory ascites due to liver cirrhosis. The Company plans to commence a randomized 24-patient Phase 2 study this year, to be followed by a larger pivotal Phase 3 clinical trial targeted to begin the first half 2021. The FDA has communicated that pending positive Phase 2 study results, a sufficiently large and well-controlled Phase 3 trial, with supportive data from the Phase 2, could potentially yield the clinical data needed to apply for BIV201 marketing approval. The Company estimates that the pivotal Phase 3 study will involve approximately 120 ascites patients. Importantly, BioVie may use the new patent-pending BIV201 prefilled syringe in the upcoming Phase 2 trial subject to conducting certain additional standard analytical testing that is expected to take approximately two weeks. Room temperature stability of the prefilled syringe has been confirmed at 6 months, with the potential for 12 months or up to two years of stability. Room temperature storage presents a key product differentiation versus terlipressin products in countries where the drug is approved. To the best of the Company's knowledge, all other terlipressin products sold globally must be stored under refrigeration and there is no prefilled syringe format of terlipressin available for treating patients in these countries. Terlipressin, which is not available in the US or Japan, is often sold as a lyophilized powder for reconstitution in hospital pharmacies in Europe and Asia. The traditional powder format is satisfactory for hospital use, but creates a logistical challenge when administering terlipressin via ambulatory infusion pump in patients located outside the hospital setting. To solve this challenge, the Company developed a patent-pending liquid formulation for delivery via prefilled syringe. This novel drug delivery system is expected to simplify at-home patient treatment and improve patient compliance by enabling easy injection of the liquid concentrate into the IV bag connected to the infusion pump. It avoids the manual mixing of minute (2 - 4 mg) quantities of terlipressin powder in saline solution, thereby reducing the possibility of dosing errors during reconstitution, and is expected to improve drug solution sterility. BIV201 has received an Orphan Drug designation from the FDA for the treatment of ascites. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the United States for the designated use. In addition, the Company has begun applying for global patent protection of our proprietary liquid formulation of terlipressin. This could eventually provide up to 20 years of patent coverage in each country for which the Company seeks patent protection, including the US, according to the patent laws of that country.

08:35 EDT DarioHealth announces two remote patient monitoring agreements - DarioHealth announced that the company has signed its first two remote patient monitoring agreements. Remote patient monitoring will allow treating physicians to continue to be the primary source of medical advice for patients in between office visits, potentially preventing unnecessary and unplanned hospital visits. Dario's RPM product integrates the company's existing open platform, application technology, and the DarioEngage coaching platform to provide physicians, health systems and large provider groups with a turnkey solution to leverage the recently approved remote patient monitoring codes. Effective January 2020, physicians can bill three new CMS approved RPM codes for Medicare members. In addition to improving the quality of care this can provide up to approximately $1,500 per patient per year in revenue to providers.

08:33 EDT Marathon Patent Group purchases 500 S19 Pro ASIC Miners - Marathon Patent Group announced the purchase of an additional 500 of the latest generation Bitmain S19 Pro Miners. These 500 miners will produce 110 TH/s and generate 55 PH/s of hashing power, bringing the Company's total Hashrate to approximately 240 PH/s when fully deployed. This compares to the Company's previous S-9 production of 46 PH/s. The purchase price paid was $1,190,000. The Company expects to take delivery of these latest units by the end of September. On May 11, 2020, Marathon announced the purchase of 700 M30S+ miners which now have been fully installed and are operational. On May 12, 2020, the Company announced the purchase 660 Bitmain S19 Pro Miners followed by the announced purchase of an additional 500 on May 19, 2020. Today's announcement of the purchase of an additional 500 S19 Pro Miners brings the total state of the art, next generation miners purchased in the past month to 2,360 units. The Company is expecting delivery and installation of 1,160 Bitmain S19 Pro ASIC Miners in approximately the next 30-60 days, followed by the remaining 500 shortly thereafter.

08:32 EDT Keurig Dr Pepper announces equity distribution by majority shareholder - Keurig Dr Pepper announced that JAB Holdings B.V. has indicated its intention for its majority-owned Maple Holdings B.V. subsidiary to convert a portion of the interest of its minority partners into shares of KDP that will become freely tradeable after a lock-up period. JAB and Maple will collectively remain a controlling shareholder of KDP following the distribution. To affect the transaction, Maple intends to distribute approximately 143M shares of KDP stock that Maple currently holds, representing approximately 10.1% of the outstanding common stock of KDP. The minority partners involved in the transaction are affiliates of BDT Capital Partners, affiliates of Quadrant Capital Advisors and the JAB Consumer Fund. These minority partners have been invested in KDP, through their interests in Maple, since the JAB-led acquisition of Keurig Green Mountain, which was announced in 2015, and will continue to retain stakes in Maple following the distribution. All of the minority partners receiving shares as part of this distribution will be subject to lock-up provisions on the distributed shares for six months on 50% of the shares and 12 months for the remaining distribution. Following the distribution and lock-up period, JAB and Maple will collectively own 52.6% of KDP, Mondelez International, Inc. will continue to own 13.1% and the public float will increase to 34.3%, including shares held directly by the minority partners.

08:28 EDT Micron donates $1M to communities devastated by COVID-19 - Micron Technology announced it provided $1M to support underserved communities disproportionately affected by the coronavirus. The grants will be used to aid front-line organizations focused on ensuring basic human needs, empowerment and education for marginalized individuals and families. Micron will commit $500,000 to the BET + UWW COVID-19 Relief Fund, established by Black Entertainment Television in partnership with United Way Worldwide, to provide financial, educational and community support. Micron's $200,000 grant to Hispanics in Philanthropy will assist Latino organizations in the U.S. offset unexpected costs incurred by the rapidly changing situation from the coronavirus. Techbridge Girls will leverage Micron's $100,000 donation to advance STEM education and encourage K-12 students to pursue engineering-related careers. The funding will enable Techbridge Girls to create online, high-quality programs, including inspirational STEM enrichment activities. Additionally, Micron will make grants to the following organizations: $50,000 to the East Oakland Youth Development Center, $50,000 to the San Jose Digital Inclusion Partnership, $50,000 to the National Center for Children and Families serving the entire Washington D.C. Metropolitan Area, $25,000 to the San Francisco chapter of Friends of the Children, $15,000 to the Wellspring Women's Center in Sacramento, and $10,000 to the Folsom chapter of Blessings in a Backpack.

08:26 EDT CHF Solutions ships Aquadex SmartFlow products to Florida - CHF Solutions announced that it has sold Aquadex SmartFlow consoles and disposables to a critical care hospital for use in the treatment of COVID-19 patients in Central Florida. Managing fluid balance in critically ill COVID-19 patients is important to avoid potentially life-threatening complications, such as volume overload, acute respiratory distress syndrome, and other conditions related to progressive congestion. Because of this need, several hospitals across the country have included a simplified ultrafiltration system, such as Aquadex therapy, into their treatment protocol for fluid management for COVID-19 patients, especially when dialysis equipment and staff are limited. As recently cited, isolated ultrafiltration is an optimal strategy that primarily focuses on fluid extraction and optimization of volume status. The Aquadex SmartFlow system, a portable ultrafiltration device with small extracorporeal volume, provides a predictable method for fluid extraction, making it more likely to achieve precise fluid balance in these patients.

08:22 EDT ATIF Holdings announces additional $800,000 consulting service agreement - ATIF Holdings announced that the Company, through Qianhai Asia Time International Financial Services Co., the Company's variable interest entity in China, entered into a consulting service agreement, dated June 9, 2020, to act as a financial advisor for Yinfu Gold Corporation, an emerging growth company specializing in new-emerging application industries of Internet Technology, Artificial Intelligence and the Internet of Things. The Agreement was signed in anticipation of ELRE's uplisting to Nasdaq or New York Stock Exchange. Pursuant to the Agreement, ATIF Shenzhen agreed to provide consulting services including but not limited to equity ownership verification, equity restructuring, asset and business model optimization to help ELRE to be listed Nasdaq or New York Stock Exchange. As consideration, ELRE agreed to pay ATIF Shenzhen a fixed consulting fee of 800,000, to be paid in installments and subject to certain conditions.

08:20 EDT Pressure BioSciences: SkinScience Labs receives $3.5M order for hand sanitizer - Pressure BioSciences announced that its merger partner SkinScience Labs, has received an initial $3.5M dollar order for its newly developed, premium, dermatological hand sanitizer product. PBI announced plans on April 30 to acquire SkinScience Labs, parent company of Dr. Denese skin care and anti-aging product lines. PBI's rights to acquire SkinScience Labs arise through its planned acquisition of Cannaworx, announced on April 28.

08:17 EDT Bloomin' Brands reports weekly U.S. comparable restaurant sales update - Reports week ended May 10 comparable restaurant sales down 42.2%. Reports week ended May 17 comparable restaurant sales down 39.1%. Reports week ended May 24 comparable restaurant sales down 34.7%. Reports week ended May 31 comparable restaurant sales down 29.5%. Reports week ended June 6 comparable restaurant sales down 28.3%.

08:15 EDT Establishment Labs receives CE Mark for Motiva Flora Tissue Expander - Establishment Labs announced it has received CE Mark for the Motiva Flora Tissue Expander. The Motiva Flora Tissue Expander, with its proprietary SmoothSilk surface, is the only such product with an integrated RFID port with no magnets, allowing for use of the expander safely alongside MRI scanning. Recently published research1 concluded that Flora offers potential advantages for patients undergoing MRI compared with tissue expanders that have magnetic ports that create substantial signal losses and distortion on MR images. Motiva Flora and Motiva Implants offer the SmoothSilk surface, a bioengineered nanosurface that has demonstrated a very low rate of capsular contracture and no reported cases of BIA-ALCL to date. Establishment Labs intends to extend its presence into the reconstruction market with the introduction of its Flora tissue expander alongside Motiva Implants. The Company expects to immediately commence pre-marketing activities in Europe for Flora in preparation for a broad commercial launch in early 2021.

08:13 EDT Diffusion Pharmaceuticals files CTA for European Phase 1a/1b study of TSC - Diffusion Pharmaceuticals announces the submission of a Clinical Trial Application to the Romanian National Agency for Medicines and Medical Devices to initiate a Phase 1a/1b clinical trial of the Company's novel oxygenation-enhancing product candidate trans sodium crocetinate for the treatment of hospitalized COVID-19 patients displaying severe respiratory symptoms and low oxygen levels. Low oxygen levels occur as a consequence of damage to the lungs from COVID-19 and often result in mechanical ventilation and, if that is ineffective, multiple organ failure - the leading cause of death in COVID-19 patients. Assuming NAMMD authorization of the CTA and approval by the National ethics committee under NAMMD's accelerated seven-working-day approval process, Diffusion plans to begin the 24 patient Phase 1a portion of the clinical trial by the end of Q2 2020. The entire Phase 1a/1b trial will enroll approximately 224 patients and is expected to last approximately 12 months. First data readout on the initial 24 patients is expected in Q3 2020, followed by an interim readout on 50 patients in Q4 2020 and final data in Q2 2021. This first European study will be facilitated by ARENSIA Exploratory Medicine GmbH and conducted at the National Institute of Infectious Diseases, Bucharest, Romania, with the Institute's Managing Director, noted infectious diseases researcher Prof. Adrian Streinu-Cercel, M.D. PhD., serving as Principal Investigator. The 1a phase will be an open-label, pharmacokinetic/ pharmacodynamic, dose-finding, safety lead-in study testing TSC in 24 hospitalized, non-ventilated COVID-19 patients with documented oxygen deficiency. Upon completion and readout of the 1a phase of the study, the Company intends to commence at the NIID a Phase 1b adaptive-design, 200 patient, randomized, double-blinded, controlled study with enrollment and patient observation targeted for completion in Q1 2021 and data read-out in Q2 2021. In addition to safety and oxygenation markers, the Phase 1b portion will include functional endpoints including time-to-recovery through Day 28. Trial design and optimum endpoint selection for final analyses are subject to modification based on the interim data look in Q4 2020. The Company intends to combine these results with data from a planned similar U.S. trial to support the drug's possible approval in both Europe and the U.S. Based on detailed U.S. Food and Drug Administration guidance from a Pre-IND Meeting Request response received last month, the Company expects to file an Investigational New Drug application later this month, with a response from the FDA expected on an accelerated basis.

08:12 EDT Bloomin' Brands provides business update related to COVID-19 - Bloomin' Brands announced a business update related to COVID-19 as well as recent sales results and details on cash utilization and liquidity. CEO David Deno said, "The priorities for Bloomin' Brands remain unchanged as we navigate these challenging times. We are focused on taking care of our people and serving food in a safe environment that protects both our Team Members and customers. Since the onset of the pandemic, we have been nimble in adapting our business. This included a pivot to an off-premises model as dining rooms were forced to close. We were able to triple our off-premises sales per restaurant while our dining rooms were closed. Starting in early May states began the process of partially re-opening their economies. Our decision to not furlough any employees during this pandemic has allowed us to quickly prepare our restaurants for the reopening of dining rooms in a safe and efficient manner. As of June 7, 2020, over 760 company-operated U.S. restaurants (approximately 74% of U.S. restaurants) have reopened with limited in-restaurant dining capacity in accordance with local mandates. At Outback Steakhouse, we had 373 restaurants open for dine-in service at limited capacity during the full week ended June 7, 2020. Comparable restaurant sales at these locations were down 13.6% from the prior year. We are encouraged by these sales trends as we begin to reopen our dining rooms. By the end of the month, we expect to have substantially all our domestic restaurant dining rooms opened with limited seating capacity. We continue to adhere to the strongest of safety measures as we open dining rooms. These measures include additional sanitation and disinfecting practices, enhanced hand-washing protocols, use of gloves and facial protection for our employees, and we are also providing contactless payment options for our customers. In addition, each dining room seating configuration has been modified to adhere to social distancing and reduced capacity standards, and we are leveraging our table management notification system to allow guests to wait in their cars for their table. We are tightly managing our cash usage and the recent convertible note transaction has further enhanced our liquidity position. We believe we are well positioned to build upon our recent success and emerge a stronger company as we navigate the ongoing crisis. As of this morning, our total liquidity position was $493 million, which includes approximately $128 million of cash and $365 million of capacity on our revolving credit facility. This liquidity position includes the $202 million net proceeds from the recent convertible note offering. Our liquidity position over the last several weeks has improved due to increased sales performance, working capital inflows, and earned tax credits for employee relief pay related to the CARES Act."

08:10 EDT BeyondSpring announces anticipated milestones - The following outlines the Company's anticipated upcoming milestones and projected timelines: Interim topline data readout for PROTECTIVE-2 Phase 3 for CIN - June 2020. Final data readout for PROTECTIVE-2 Phase 3 for CIN - H2 2020. Final data readout for PROTECTIVE-1 Phase 3 for CIN - H2 2020. NDA submission for Plinabulin for CIN in the U.S. - H2 2020. Final data readout for DUBLIN-3 for NSCLC - H2 2020. NDA submission for Plinabulin for NSCLC in China - H2 2020. NDA submission for Plinabulin for NSCLC in the U.S. - H1 2021.

08:09 EDT Exelixis initiates CONTACT-01 trial - Exelixis (EXEL) announced the initiation of CONTACT-01, a global phase 3 pivotal trial of cabozantinib in combination with atezolizumab in patients with metastatic non-small cell lung cancer, or NSCLC, who have been previously treated with an immune checkpoint inhibitor and platinum-containing chemotherapy. Two additional phase 3 pivotal trials in metastatic castration-resistant prostate cancer and renal cell carcinoma are planned as part of the clinical trial collaboration between Exelixis and Roche (RHHBY).

08:07 EDT Front Yard says Altisource made 'inaccurate, misleading' statements - The Board of Directors of Front Yard Residential Corporation (RESI) issued a letter to its stockholders with respect to its upcoming annual meeting of stockholders. The letter read, in part, "In a recent letter to Front Yard stockholders, Altisource Portfolio Solutions S.A. (ASPS) announced that it is conducting a withhold vote campaign with respect to the re-election of certain of Front Yard's Board members. As part of its campaign, we believe that ASPS made inaccurate and misleading statements about our Company, Board and management. While we do not believe it is productive to address every inaccuracy or misleading statement made by ASPS, we do feel it is very important that stockholders understand the views of Front Yard's Board and management. The Front Yard Board and management team remain fully committed to and focused on enhancing value for our stockholders, and we will continue to take actions to achieve this important objective. The Front Yard Board demonstrated its commitment to driving stockholder value when, in May 2019, the Board initiated a comprehensive review of strategic alternatives available to the Company. As part of that review, the Board considered a full range of strategic options to maximize shareholder value, including the potential termination of the asset management agreement with Altisource Asset Management Corporation and internalization of the Company's asset management function, a liquidation or partial liquidation of the Company, strategic sales of portions of the portfolio, formation of a joint venture or strategic partnership and a sale of the Company. All options were on the table...While we, like many of Front Yard's stockholders, are disappointed that the transaction with Amherst Residential could not proceed, we are highly focused on continuing the upward trend in Front Yard's operational performance - the first quarter of 2020 was Front Yard's best ever operational quarter - and we believe that this trend will continue. We are confident that Front Yard and the single-family rental industry are well-positioned for continued success that will build long-term stockholder value. It is critical that the Board and Front Yard management team remain focused on the business...We believe Front Yard is on the path to generate sustained long-term financial and operating performance, and we are committed to pursuing a course that creates value for all stockholders. The Board will, however, continue to evaluate all strategic options to enhance value for Front Yard stockholders, including the potential termination of the AMA and internalization of the Company's asset management function, a potential sale of the Company and other transactions, strategic investments and/or dispositions that can optimize returns for our stockholders. The Front Yard Board has the right to terminate the AMA for convenience under the terms of the agreement at any time and, as part of continuing to consider what is in the best interests of Front Yard stockholders, the Board will consider whether and when to terminate the AMA."

08:06 EDT Philip Morris appoints Suzanne Rich Folsom as General Counsel - Philip Morris International announced that Suzanne Rich Folsom has been appointed Senior Vice President and General Counsel, leading Legal, Ethics & Compliance, effective July 1. PMI said in a release, "She succeeds Marc Firestone, who will retire later this year. Since January 2018, Mr. Firestone has held a dual role at PMI: President, External Affairs and General Counsel. He will continue to lead the company's External Affairs function until a successor is appointed. She comes to PMI from Manatt, Phelps & Phillips, LLP, where she co-chaired the Investigations, Compliance, and Strategic Response Group and was a member of the Government & Regulatory and Cyber & Privacy groups."

08:03 EDT TEN, Ltd. agrees to long-term accretive charters - The primary objective of management since the beginning of the year has been to ensure that the fleet's crew is safe and sound in these challenging times, especially as government actions around the world have applied harsh, but necessary restrictions to contain the Covid-19 pandemic. In this unprecedented environment, with 65 vessels navigating all corners of the world and crewed by 2,000 seafarers, management's goal has been to ensure their health and safety. Duringthis period, the silver lining has been the strength of the tanker market, due to its solid fundamentals and the strong demand for our services during the first six months of 2020. In this environment, TEN took the opportunity to agree long-term accretive charters, that will secure the Company's positive performance for the remainder of 2020. Maintaining a strong balance sheet by increasing liquidity and reducing debt obligations continues to be a priority. As previously stated, it remains management's intention to initiate the, at par, redemption of its Series C preferred shares next quarter. "In the first quarter of 2020, the pandemic was accompanied by a strong tanker market that continued well into the second quarter. During that period, TEN fixed long-term charters for its vessels that will secure positive returns for the remainder of the year and beyond," Mr. George Saroglou, COO of TEN commented. "Management continues to be in discussions with first-class charterers for similar accretive employments to safeguard cash flow visibility, a core element in TEN's strategy. The safety of our seafarers was, is and remains our top priority as TEN continues its long established and market tested operating model to achieve the highest utilization levels and long-term profitability. This is the fourth and most challenging crisis we have successfully navigated in 28 years of operations. We would like to thank all our colleagues for their efforts during these extraordinary times and wish them to remain safe and healthy."

08:02 EDT TEN, Ltd. increases special dividend 50% to 7.5c per share - Following the March 24, 2020 announcement of a 5 cents per common share dividend, the Company's Board of Directors have subsequently approved to increase, for this time, that amount by 50% and pay a total of 7.5 cents per common share on June 26, 2020. The record date has been set for June 22, 2020 with ex-dividend date June 19, 2020.

08:00 EDT Moderna expects to begin Phase Phase 3 study of COVID-19 vaccine in July - Moderna announced progress on late-stage development of mRNA-1273, the Company's mRNA vaccine candidate against COVID-19. Moderna said in a release, "Moderna has finalized the Phase 3 study protocol based on feedback from the FDA. The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants enrolled in the U.S. and is expected to be conducted in collaboration with the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health, or NIH. The trial's primary endpoint will be the prevention of symptomatic COVID-19 disease; key secondary endpoints include prevention of severe COVID-19 disease (as defined by the need for hospitalization) and prevention of infection by SARS-CoV-2, the virus that causes COVID-19. The primary efficacy analysis will be an event-driven analysis based on the number of participants with symptomatic COVID-19 disease. Based on the results of the Phase 1 study, the 100 microgram dose level was chosen as the optimal dose level to maximize the immune response while minimizing adverse reactions. Moderna has completed manufacture of vaccine required to start the Phase 3 study. The Company expects dosing in the Phase 3 study to begin in July. With the Phase 3 dose being finalized at 100 microgram, the Company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021 from the Company's internal U.S. manufacturing site and strategic collaboration with Lonza."

07:51 EDT DREAM Unlimited closes on sale of indirect interest in renewable power portfolio - Dream Unlimited Corp. provided a business update on transactional and operational activity for the month of June 2020. The company said, "Dream has now closed on the sale of its indirect interest in a renewable power portfolio to Potentia Renewables Inc. In addition, we are near completion of the re-financing of the Distillery District, which comprises 395,000 sf of commercial and retail GLA in downtown Toronto. In aggregate, these transactions will generate cash of $130 million for Dream, which will be used to pay down corporate level debt and provide additional liquidity for the Company. We are pleased to announce that Dream has entered into an agreement to acquire a 50% interest in a portfolio of apartments located in Dallas, Texas, expected to close in early July 2020. The 1,200-unit portfolio will be acquired alongside Pauls Corp. for approximately $150,000 per unit, for a total investment of $15 million USD, after assuming agency debt and mezzanine financing at Dream's share. Our current intent is to hold the portfolio for the long-term, which may become the seed investment for our recently announced private equity arm, Dream Equity Partners. Through the launch of Dream Equity Partners, we intend to leverage our core competencies in managing and developing office, multifamily, industrial and mixed-use assets in Canada, the United States and Europe focused on core, core-plus and value-add investments. Dream has approved the commencement of servicing of the first phase of Alpine Park, within Providence, located in the south west of Calgary. We consider this to be a significant milestone for Dream as the first phase of Alpine Park was originally acquired in 1997. Based on current market assumptions, we expect initial phases of Alpine Park to generate income between 2021 - 2026 and cash of approximately $70 million. The first phase of servicing will require an additional $35 million of cash and we anticipate having $36 million of committed sales by the end of June 2020. Our initial phases of Alpine Park comprise 136 acres of Dream's total 1,600-acre landholding within Providence. Over the last few years we have reduced working capital in Western Canada, bringing in a majority partner in Glacier Ridge, selling parcels, lots and houses, and selectively starting communities that are quickly cash flow positive. We have generated approximately $60 million of cash from Western Canada in 2020 and expect, over time, to earn profits and generate cash flow while reducing our overall investment in the 9,100 acres of land within this division. Our development projects continue to progress steadily despite the ongoing challenges presented by the COVID-19 pandemic. Consistent with prior guidance, we anticipate further occupancy income and final unit closings to occur in 2020 at Riverside Square, BT Towns, Canary Block and Kanaal, our condominium projects located in downtown Toronto and Ottawa. In addition, we continue to make progress on the development of our income properties including: Block 211 of Zibi, which has been leased to the Federal Government of Canada and will be completed by late 2021; our Brighton Village Centre purpose-built rental building in our master-planned community of Holmwood in Saskatoon; and Block 8 within our West Don Lands development, all of which will further increase the value of our best-in-class income properties upon completion."

07:47 EDT Marcus Theatres announces phased reopening plan - Marcus Theatres, a division of Marcus, announced its plan to reopen theatres. It begins on June 19, with six theatres, including Marcus Ridge, Renaissance, BistroPlexSM and Valley Grand Cinemas in Wisconsin; Majestic Cinema of Omaha in Nebraska; and the Roswell Movie Tavern in Georgia. Marcus said in a release, "These initial locations feature enhanced protocols in accordance with current local health and safety guidelines, and will help fine-tune future phases of theatre reopenings which are coming in the weeks ahead, and in time for summer blockbusters based on when studios release new films. As part of the initial reopening experience, Marcus Theatres is introducing its "Movie STAR" approach, which incorporates new health and safety measures and is in alignment with Centers for Disease Control guidelines. Everyone can be a Movie STAR and play a role in creating a safe environment with social distancing; Thorough cleaning; App and website ordering of tickets, food and concessions for no-to-low contact interactions; and respecting each other by following these new protocols. Policies and guidelines will continue to evolve with time and will be assessed and updated on an ongoing basis."

07:42 EDT Medipharm Labs 'moving forward in securing new contracts' - MediPharm Labs provided a summary of material business developments following its press release dated May 14, 2020. The company said, "On June 8, 2020, the Company successfully completed a private placement, securing gross proceeds of $38.7M, half of which are being held in escrow pending satisfaction of certain conditions including shareholder approval. This strategic capital provides enhanced balance sheet strength and flexibility as the Company accelerates the launch of Cannabis 2.0 offerings and new product formats, increases exports of Active Pharmaceutical Ingredients, and begins delivery on multiple global supply contracts. With this capital, Company is also moving forward in securing new contracts, including with large pharmaceutical and CPG companies, as it navigates the economic recession created by the COVID-19 pandemic. Expanded portfolio of global supply agreements; with new customer agreements in Australia, New Zealand and first UK-based customer. Entered into an agreement with Avicanna to produce Rho Phyto medical cannabis products and Pura Earth topicals under license for commercial sales through Medical Cannabis by Shoppers and received a license to use proprietary Avicanna formulations to develop additional MediPharm Labs and white label branded products for domestic and international markets. The Company expanded its pharma-quality MediPharm Labs family of products with the launch of its MediPharm Labs CBD50 Plus Formula, a formulated, high potency oil for medical and adult-use consumers. Introduced and completed delivery of the highly anticipated and innovative suite of Ace Valley Vape products under a white label agreement in several Canadian markets. Entered white-label supply agreement with Argentia Gold Corporation, a Canadian vertically integrated licensed producer, to bring premium cannabis-infused products to Atlantic Canada. As previously announced, the Company reported that it is relying on the exemption provided in Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Finance Requirements to postpone the filing of its unaudited interim financial statements and management discussion and analysis for the three month period ended March 31, 2020. Pending the filing of Interim Financial Information, members of the Company's management and other insiders remain subject to a trading blackout reflecting the principles contained in section 9 of National Policy 11-207 Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictions."

07:38 EDT Crinetics reports completion of half of patients in Phase 2 trial of paltusotine - Crinetics Pharmaceuticals announced that over 50% of the patients enrolled in the ACROBAT Edge Phase 2 clinical trial have completed the study. So far, 28 of the 47 patients enrolled have completed the study, which is investigating the effects of once daily oral paltusotine on IGF-1 levels after switching patients from injectable depot therapy. Based on the results of the previously announced interim analysis, Crinetics believes that the data from Edge is supportive of moving forward into Phase 3. Enrollment in the ACROBAT Evolve study was discontinued at the same time that enrollment in Edge was completed. Patients already enrolled in Evolve have continued in the study. Topline data from the 47 patients in Edge, 25 of which entered the trial on octreotide LAR or lanreotide depot monotherapy, and the 13 patients in Evolve is expected in the fourth quarter of 2020. To date, the company has not experienced significant disruptions in completing the Edge and Evolve studies due to the COVID-19 global pandemic.

07:36 EDT Radient makes bioU products available at Medical Cannabis by Shoppers - Radient Technologies announces that its recently launched bioU branded products are now available through Medical Cannabis by Shoppers, a subsidiary of Shoppers Drug Mart. The bioU brand was created exclusively for Medical Cannabis by Shoppers and is now available across Canada. bioU products have been scientifically designed by Radient to provide a high quality, consistent, broad spectrum oil formulations to medical users. The first series of products to launch is the USpray line of extracts which come in a convenient, precise dosage oral spray format. A CBD dominate and balanced formulation are now available, with a THC dominate formula expected shortly. The Company has also received the approval from the TSX Venture Exchange for a series of shares for debt agreements with various of its creditors, which was previously announced in a press release dated May 8, 2020 under the terms and conditions noted below. The Company has issued 6,716,252 units to a number of third-party creditors in exchange for the settlement of $1,108,182 owed by the Company to such creditors. Each unit has a deemed value of $0.165 per unit and each unit includes one share and one-half of one common share purchase warrant. Each whole warrant will have a term of 24 months and will be exercisable at $0.30 for one Radient common share. The Company has also issued 382,691 common shares to a third-party creditor in exchange for the settlement of $63,144 owed by the Company to such creditor. Additionally, the Company has issued 841,585 common shares to certain officers and directors in exchange for the settlement of $138,861 owed by the Company to such individuals. The Radient shares issued under these agreements have a deemed value of $0.165 per share. Securities issued under the above arrangements are subject to a 4 month statutory hold period.

07:33 EDT Reata Pharmaceuticals says financing extends cash runway through end of 2023 - "This $350M financing further strengthens Reata's balance sheet, and extends Reata's cash runway through the end of 2023. It positions us to make strategic investments to further expand our development and commercial capabilities in preparation for the potential approval and launch of our drugs," said Manmeet Soni, COO and CFO at Reata.

07:28 EDT Blink Charging announces JV agreement with Envoy Technologies for EVs - Blink Charging announced a joint venture agreement with Envoy Technologies. The multi-year agreement is designed to bring electric vehicles and EV charging to urban residents across the United States through the deployment of Blink charging stations across Envoy property locations. Envoy partners with some of the largest commercial real estate companies in the country to provide exclusive electric car-sharing as a property amenity for apartments, hotels, and workplaces; Mobility as an Amenity. The turnkey solution includes EV charging infrastructure and Blink will be among the preferred EV charging station providers for the Envoy car-sharing program as well as additional charging stations at client properties, available to the public, for use by all EV drivers. Envoy's community-based electric vehicle mobility platform grew 350% over the past two years. The first deployments of 46 Blink IQ 200 charging stations have been completed early in 2020 and are paving the way for accelerated deployments throughout the year. The IQ 200 charging stations are currently the fastest Level 2 chargers available, delivering up to 65 miles of charge in an hour. No assurances can be given as to the number of chargers that will be deployed over the next 12 months or succeeding years, or the price of chargers sold to users or the resulting sales revenue to the Company, pursuant to the Envoy agreement.

07:25 EDT Akoustis signs purchase agreement with new Tier-1 OEM for WiFi 6E - Akoustis Technologies announced that it has signed a strategic purchase agreement with a new tier-1 enterprise WiFi OEM customer for multiple, new WiFi 6E XBAW filters operating above 5 GHz. The new filters will operate within the existing 5 GHz unlicensed spectrum as well as the 5.9-7.1 GHz bands recently approved by the FCC for next generation WiFi 6E CPE devices. Product design for each of these new filters has begun and Akoustis expects to deliver first samples by December 2020 for characterization and final customer acceptance. The XBAW filters target inclusion in enterprise-class WiFi CPE products that are expected to go into production in the first half of calendar 2021. Akoustis is developing these new XBAW filters in parallel to standard WiFi 6E filters currently in development for catalog customers, including the 5.5 GHz filter module announced on June 8, 2020.

07:22 EDT Regeneron-s anti-viral cocktail featured in two Science publications - Regeneron announced that Science has accepted for publication two papers describing the creation of its novel two-antibody cocktail, REGN-COV2, and its potential to diminish risk of viral escape by effectively binding to the virus's critical spike protein in two separate, non-overlapping locations. REGN-COV2 has entered human clinical trials. The first paper describes Regeneron's parallel efforts using both humanized VelocImmune mice and blood samples from recovered COVID-19 patients to generate a collection of antibodies targeting multiple different regions of the critical receptor-binding domain of the SARS-CoV-2 spike protein. By blocking its interaction with the host cell, antibodies are able to neutralize the virus and block infection. The concept that drug cocktails can prevent viral escape has previously been demonstrated for traditional antiviral drugs used to treat HIV and other viruses. Regeneron now reports the realization that this can also be true for antibody-based therapies as reported in the second paper, which further defines the protective value of the multiple-antibody approach against SARS-CoV-2 specifically. This research for the first time demonstrates that escape mutants could not be efficiently generated following exposure to the REGN-COV2 cocktail since it utilizes two antibodies that can simultaneously bind to distinct regions of the RBD.

07:18 EDT GasLog Partners, GasLog announce availability of sustainability reports - GasLog Ltd. (GLOG) and GasLog Partners LP (GLOP) announced that their 2019 Sustainability Reports are available for download. Paul Wogan, CEO of GasLog, stated "Producing our first Sustainability Report has allowed us to focus on where we are in terms of our environmental, social and governance practices. We proudly demonstrate in this inaugural report how we have already embedded many ESG elements into our controls and processes and how we will ensure that our ESG standards are aligned to achieve excellence for the benefit of all our stakeholders. We have also set a clear roadmap for further enhancements to allow us to continue to deliver LNG, a cleaner alternative energy source to coal and other hydrocarbons, for our customers in a responsible and sustainable manner." Andy Orekar, CEO of GasLog Partners, stated "Although we rely on our general partner, GasLog, for the management and operation of our ships, in this report our stakeholders will see the Partnership has its own clear vison and commitment from its Board of Directors to a sustainability strategy. High levels of environmental, social and governance standards are embedded in the GasLog Partners culture and led from the Board by example. We believe this report transparently demonstrates our current position and shows a vision for the way ahead."

07:15 EDT First Majestic acquires Silver Stream on First Mining's Springpole project - First Majestic Silver announced that it has agreed to acquire from Gold Canyon Resources Inc., a wholly-owned subsidiary of First Mining Gold Corp., a stream on 50% of payable silver produced from the Springpole Gold Project located in Ontario, Canada. First Majestic will pay First Mining total consideration of $22.5 million in cash and shares, over three payments, for the silver stream which covers the life of the Project. In addition, First Majestic will make ongoing cash payments of 33% of the silver spot price per ounce, to a maximum of $7.50 per ounce, for all payable silver delivered by Springpole. First Mining is also granting First Majestic 30 million common share purchase warrants, each of which will entitle the Company to purchase one common share of First Mining at C$0.40 over a period of five years commencing at closing. First Majestic acquires a stream on 50% of the payable silver produced from Springpole over the life of the project for 33% of the silver spot price per ounce, to a maximum of $7.50 per ounce, for all payable silver delivered. According to the 2019 Preliminary Economic Assessment, average silver production from Springpole in years two through nine of the mine plan is expected to be 2.4 million ounces of silver per year. A total of 22 million ounces of silver is expected to be recovered over the life of the project - of which 50% would be purchased by First Majestic. Springpole is one of Canada's largest, undeveloped gold projects with permitting underway and the results of a Pre-Feasibility study anticipated in early 2021. The project contains NI 43-101 compliant resources of 24.19 million ounces of silver in the Indicated category and 1.12 million ounces of silver in the Inferred category, plus 4.67 million ounces of gold in the Indicated category and 0.23 million ounces of gold in the Inferred category. The Springpole Project offers substantial exploration upside over its large land holdings of 41,913 hectares which are fully encompassed under the silver streaming agreement. Increases First Majestic's silver exposure and is the Company's first investment outside of Mexico in a mining friendly jurisdiction within Canada. Provides First Majestic with equity upside potential as First Mining increases shareholder value throughout the Springpole Pre-Feasibility and permitting process. Closing of the transaction is expected to occur in early July 2020 and is subject to the completion of certain corporate matters and customary conditions.

07:12 EDT Pluristem announces activation of clinical sites in Phase II COVID-19 ARDS trial - Pluristem Therapeutics announced the activation of clinical sites and initiation of enrollment in its Phase II U.S. Food and Drug Administration study of PLX cells for the treatment of severe COVID-19 complicated by Acute Respiratory Distress Syndrome. The Company is focused on expanding to clinical sites throughout the U.S. in accordance with the changing dynamic spread of the COVID-19 pandemic, using its advanced operational capabilities and cold chain agility. The trial is expected to include up to 25 sites. The randomized, double-blind, placebo-controlled, multicenter, parallel-group 140 patient study is evaluating the efficacy and safety of intramuscular injections of PLX-PAD for the treatment of severe COVID-19 cases complicated by ARDS. The primary endpoint is the number of ventilator free days during the main 28-day study period. Safety and survival follow-up will be conducted at week 8, 26 and 52. Secondary efficacy endpoints include all-cause mortality, duration of mechanical ventilation, ICU free-days, and hospitalization free-days.

07:09 EDT Amag Pharmaceuticals CFO, COO Edward Myles to depart - AMAG Pharmaceuticals announced that Edward Myles, CFO and COO, is leaving the Company. Brian Piekos, SVP of Finance, has been appointed interim CFO and will become a member of the company's Executive Leadership Team. Anthony (Casciano has been appointed COO and will add significant operational responsibilities to his role in addition to leading commercial operations. Both appointments are effective immediately.

07:06 EDT Magenta Therapeutics, NMDP announce clinical collaboration for MGTA-145 - Magenta Therapeutics and the National Marrow Donor Program, or NMDP, announced a clinical collaboration agreement to evaluate the potential utility of MGTA-145, Magenta's investigational first-line stem cell mobilization program, for mobilizing and collecting hematopoietic stem cells from donors in a single day and then using them for allogeneic transplants in patients. This life-saving procedure is currently used in approximately 28,000 patients in the U.S. and Europe each year, but approximately 62,000 additional eligible patients do not receive an allogeneic transplant due to challenges, including difficulty with the donation process. Under the collaboration, Magenta and NMDP/Be The Match will run a Phase 2 clinical trial of MGTA-145 to mobilize and collect hematopoietic stem cells from donors which will then be transplanted into patients with blood cancers in need of a stem cell transplant. The number of stem cells mobilized, engraftment function and benefit to disease will be measured. Magenta will retain all commercial rights to MGTA-145. MGTA-145, a CXCR2 agonist, works in combination with plerixafor, a CXCR4 antagonist, to harness the physiological mechanism of stem cell mobilization into peripheral blood. MGTA-145 achieved all of the safety and activity endpoints in the recently completed Phase 1 trials in over 100 volunteers. Results showed that MGTA-145, in combination with plerixafor, enabled safe, same-day dosing, mobilization and collection of superior functional hematopoietic stem cells for transplant compared to the current standard of care.

07:04 EDT Children's Place had 61 stores open in the U.S., Canada as of June 8 - On March 18, 2020, the Company suspended all store operations in the U.S. and Canada until further notice due to the COVID-19 pandemic. The Children's Place started reopening stores on May 19, 2020 in 10 states. The Company intends to continue to reopen stores on a phased timeline, as state and local guidelines and conditions permit, taking an informed, measured approach based on a number of factors. As of June 8, 2020, The Children's Place had 61 stores open to the public in the U.S. and Canada. Consistent with the Company's store fleet optimization initiative, the Company closed four stores in the three months ended May 2, 2020. The Company ended the quarter with 920 stores and square footage of 4.3 million, a decrease of 5.1% compared to the prior year. Since our fleet optimization initiative was announced in 2013, the Company has closed 275 stores. The flexibility provided by our lease actions allows us to target the closure of 300 additional store locations by the end of fiscal 2021, including 200 closures in fiscal 2020 and 100 closures in fiscal 2021. The Company's eight international franchise partners in 19 countries had 266 international points of distribution.

07:02 EDT EyeGate receives feedback from FDA regarding Ocular Bandage Gel - EyeGate Pharmaceuticals announced that it has received positive feedback from the FDA regarding the requested packaging for EyeGate's Ocular Bandage Gel, or OBG, eye drop. EyeGate said in a release, "OBG is being developed for corneal wound repair post photorefractive keratectomy, or PRK, surgery and for dry eye patients with punctate epitheliopathies, or PE. OBG does not include a preservative, which can be irritating and exacerbate these ocular surface indications. EyeGate is seeking to use a multi-dose preservative-free, or MDPF, bottle that is more cost effective and less wasteful compared to the standard mono-dose bottle or individual units typically used for preservative-free topical ophthalmics. The FDA has provided EyeGate with a path forward for using the MDPF bottle, requesting that EyeGate complete some additional tests prior to fully approving the bottle for use. These tests are expected to be completed in the second half of 2020 and are not expected to have an impact on EyeGate's cash runway."

06:59 EDT Lannett provides update on clinical advancement of similar insulin glargine - Lannett said that representatives from the company spoke with and received guidance from the FDA on the clinical advancement program of its biosimilar insulin glargine partnered product candidate. Lannett said in a release, "Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar. Total U.S. sales of the glargine related products, according to IQVIA, were approximately $9.5B for the 12 months ending April, although actual biosimilar market values are expected to be lower." Lannett CEO Tim Crew said, "At the Biosimilar Biological Product Development, or BPD, Type II meeting held earlier this week the FDA provided positive feedback on the clinical and Chemistry, Manufacturing and Controls, or CMC, advancement of our biosimilar insulin glargine that was consistent with our expectations. Our path forward is clear with regard to what is expected in the planned 351(k) biosimilar application, which we anticipate will be filed in calendar year 2022. We will work with our strategic partner to complete all the necessary development activity, including human clinical trials, in accordance with FDA's guidance." Crew added, "Biosimilar insulin glargine represents a significant opportunity for Lannett, given the notably large addressable market. Moreover, we believe only a relatively small number of competitors have the technical expertise and requisite resources to develop and manufacture such a complex product."

06:48 EDT CNX Resources provides operational update - CNX Resources announced an operational update. The company said, "CNX continues to optimize its long-term intrinsic value per share by safely and compliantly generating free cash flow (FCF) per share on a regular basis. The following is an update of key drivers in that effort. CNX began sculpting its production profile since May 1st, and the company has shut in as much as 375 MMcf per day of production to take advantage of the large positive spread between summer and winter natural gas prices. The company expects the shut-in amount to decline to approximately 300 MMcf per day of production by July and will adjust as conditions warrant. This production profile optimization would result in over $30 million(a) in incremental FCF over the next few years, assuming the wells are turned back online November 1st and using current forward strip pricing. In a series of related transactions, the company monetized hedges in the summer months of 2020 and added new hedges in the winter months, which locked in a significant portion of this FCF improvement. CNX continues to achieve capital efficiency improvements in its core Southwest Pennsylvania (SWPA) Marcellus Shale wells. The company's most recent eight-well Marcellus Shale pad, RHL 99, was stimulated by Evolution Well Services' electric frac fleet and averaged 1,570 lateral feet per day and a peak of 2,600 lateral feet in a 24-hour period. During stimulation of the RHL 99 pad, the company used approximately 140,000 Mcf of CNX's clean burning natural gas to power the fleet in lieu of diesel, which equates to a fuel savings of approximately $2.4 million. During the quarter, the company also drilled two SWPA Utica Shale wells at a record high pace and a record low cost. When compared to prior Pennsylvania Utica Shale wells drilled, the average drilling costs decreased from $957 per foot to $447 per foot, or a decline of 53%, with drilling times decreased by 22%. When completed, the company expects the total well costs for these two SWPA Utica wells to be approximately $1,375 per lateral foot, far below the $1,800 per lateral foot assumed in the seven-year FCF plan. Also, the company increased its estimated ultimate recovery (EUR) expectations for its most recent Central Pennsylvania (CPA) Utica well, the Bell Point 6, to a range of 4.5-5.0 Bcfe per thousand feet, which makes it the company's most productive Utica well to date. During the quarter, the substantial midstream buildout supporting the company's SWPA Marcellus Shale development plan was completed with only incremental compression and well connects needed going forward. This best-in-basin high pressure / low pressure gathering network allows the company's wells to flow at pressures that improve economics, increase ultimate recoveries, and maintain reservoir and completion integrity over the productive lives of the wells. Under the company's maintenance plan, the PDP volume will continue to grow resulting in an average base decline of approximately 20% through the 2022-2026 FCF plan."

06:35 EDT Goldman Sachs BDC, Goldman Sachs Middle Market Lending amend merger - Goldman Sachs and Goldman Sachs Middle Market Lending Corp. or MMLC have amended and restated the Agreement and Plan of Merger, dated December. GSBD and MMLC are affiliated business development companies managed by Goldman Sachs Asset Management, or GSAM. The Original Merger Agreement contained a closing condition but heightened volatility in the current market precipitated by the COVID-19 pandemic has created uncertainty as to whether this condition can be met. As a result, GSBD and MMLC amended and restated the Original Merger Agreement. The consideration has been changed from a fixed exchange ratio to a "net asset value for net asset value" exchange. GSBD would issue approximately 1.0656 shares for each MMLC share outstanding. The total share consideration to MMLC shareholders would represent a 17% premium to the pro forma MMLC net asset value. The variable cap on GSAM's incentive fees has been extended for an additional year, through the end of 2021. GSAM has agreed to reimburse GSBD and MMLC for all expenses incurred by GSBD or MMLC in connection with the transaction, subject to a cap of $4M. Prior to closing the merger, MMLC's board of directors will declare a $75M distribution to MMLC shareholders relating to the pre-closing period. This distribution is an amount equal to approximately 8.1% of MMLC's March 31, 2020 net asset value. GSAM expects the merger to be accretive to GSBD's NII per share both in the short and long-term. The merger will result in significant deleveraging, with GSBD's net debt to equity decreasing from 1.40x at March 31, 2020, to 1.14x. MMLC's revolving credit facility due March 2022 will be repaid in full and GSBD's revolving credit facility will be expanded to $1,695M. GSBD's total investments and commitments will be $3.2B. The board of directors of each of GSBD and MMLC established a special committee, consisting exclusively of their respective independent directors. The consummation of the merger is currently expected to occur in Q4.

06:32 EDT HC2 Holdings names Wayne Barr, Jr. as interim CEO, succeeding Philip Falcone - HC2 Holdings announced its Board of Directors has appointed Wayne Barr, Jr. as interim CEO. Barr succeeds Philip Falcone, effective immediately. The Board of Directors intends to commence a search for a permanent CEO and has formed a search committee comprised of Chairman Avie Glazer, and directors Warren Gfeller and Michael Gorzynski. Barr has served as a director of HC2 since January 2014, as well as serving as a director of certain HC2 subsidiaries.

06:30 EDT Volkswagen: Binding orders for ID.3 to begin June 17 in Europe - Volkswagen said in a statement on Wednesday that the final timetable for the start of Volkswagen's ID. family has been set: Binding orders for the 30,000 models making up the limited 1st Edition of the ID. 3 can be placed from June 17 in most European countries. "The Volkswagen brand's large-scale electric offensive is literally taking to the road with the ID.3. This car underscores our mission to provide locally emission-free mobility fit for everyday use and affordable for all", Ralf Brandstatter, COO of the Volkswagen brand, said.

06:03 EDT Cyren appoints James Hamilton as chairman of the board - Cyren announced that James Hamilton has been appointed by the Cyren board to serve as the company's next chairman of the board. He succeeds Lior Samuelson who has served as Cyren's chairman since 2010. Hamilton was elected to the Cyren Board in 2012, and was unanimously approved as the company's next chairman.

05:49 EDT Unilever announces plans to unify under single parent company - Unilever announced plans to unify its group legal structure under a single parent company, Unilever PLC, "creating a simpler company with greater strategic flexibility, that is better positioned for future success." After a review over the last 18 months, the board continues to believe that moving from the current dual-headed legal structure to a single parent company will bring "significant benefits" by increasing Unilever's strategic flexibility for portfolio evolution, including through equity-based acquisitions or demergers, and "removing complexity and further strengthening Unilever's corporate governance." The company said in a statement, "Unilever remains committed to its strategy of long-term growth across all three Divisions and last year began a full evaluation of its current categories and brands, with a view to accelerating the pace of portfolio change. This review has underlined how a simpler legal structure would give Unilever greater strategic flexibility to grow shareholder value, providing a catalyst for accelerated portfolio evolution and greater organisational autonomy. The ongoing strategic review of Unilever's tea business has further demonstrated that the dual-headed legal structure can create disadvantages for the Group. For example, a demerger of the tea business is one potential outcome of the review and, as was previously the case with the disposal of the company's Spreads business, this would be significantly more challenging under the current legal structure than under a single parent structure. It is also clear that the Covid-19 pandemic will create a business environment in which having as much flexibility and responsiveness as possible will be critically important." Reference Link

05:24 EDT Nokia CFO Kristian Pullola to step down, Marco Wiren appointed CFO - Nokia has appointed Marco Wiren as CFO of the company and member of the Group Leadership Team, replacing current CFO Kristian Pullola. Nokia said in a release, "Wiren will join Nokia on September 1. Wiren, who will be based at the company's headquarters in Espoo, Finland, is currently President of Wartsila Energy and Executive Vice President of Wartsila Group. Kristian Pullola, who has served as Chief Financial Officer since January 2017, will step down as CFO and leave the Group Leadership Team on August 31. He will remain with the company until around the end of the year to ensure a smooth transition."

05:20 EDT Sam's Club launches curbside pickup nationwide - Sam's Club announced the nationwide launch of curbside pickup. Sam's Club said in a release, "The service, which provides a contact-free, order online and delivery to car shopping experience, will be free for Plus-level members and is expected to be available in all clubs by the end of June. Curbside pickup is part of a list of Plus-membership benefits, which also includes early shopping hours, free shipping on most online items, 2% cash back on qualifying in-club and pickup purchases, and more. Sam's Club has been piloting curbside pickup at 16 clubs with positive results from busy families and business owners. The company is expediting the rollout - taking it to all 597 clubs - to appeal to customer shopping preferences and growing desires for convenient options that fit into consumers' lives. Plus members will be able to schedule curbside pickup orders between 7 a.m. and 8 p.m., Monday to Saturday, and 10 a.m. to 5 p.m. on Sundays. Non-Plus members will be able to use this new Plus benefit at no cost for a limited time, however, pickup times will be limited and only available 10 a.m. to 8 p.m.., Monday to Saturday, and 10 a.m. to 5 p.m. on Sundays. Members who are interested in adding this free service can upgrade to a Plus membership at any time. Sam's Club will also continue to offer its Concierge Service for seniors and high risk members every Tuesday and Thursday from 7 a.m. to 9 a.m., and Hero Hours every Sunday from 8 a.m. to 10 a.m., until further notice."